Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05516680
Other study ID # 2022-LCYJ-PY-08
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 22, 2022
Est. completion date August 2025

Study information

Verified date August 2022
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Introduction: Post-stroke depression (PSD) is the most common mental complication after stroke and has a serious impact on functional outcomes and quality of life. Antidepressants are the first-line treatment for PSD, but many reported side effects remain. Clinical research and practice guidelines have shown that electro-acupuncture and rTMS have a positive effect on PSD. This trial aims to study the efficacy and safety of electro-acupuncture and a modern MRI-navigated rTMS for PSD and to explore its fMRI-based central mechanism on depression. It is hypothesized that electro-acupuncture and MRI-navigated rTMS treatment improves depressive symptoms, neuro-patho-physiological behaviors, quality of life and central response in PSD. Methods: In this randomized, controlled, assessors-blinded trial, sixty-four patients with PSD will be randomly allocated into the experiment group (n=32) or control group(n=32) . The experiment group will receive electro-acupuncture and MRI-navigated rTMS, and the control group will receive MRI-navigated rTMS treatment, in 12-20 sessions over 4 weeks. In addition, ten healthy people for fMRI scanning will be recruited as a healthy control group without any intervention. The primary outcome is the change from baseline in the Hamilton Depression Scale-24 items (HAMD-24) scores at week 4. The primary analysis of central mechanism mainly involves cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity based on fMRI at 0-wk and 4-wk. Secondary outcomes include the neuro-patho-physiological and quality of life changes in cortical excitability with motor evoked potential test(MEP), National Institutes of Health Stroke Scale(NIHSS), EuroQol Five Dimensions Questionnaire(EQ-5D) Scale, Modified Barthel Index(MBI) Scale and Short Form-Health Scale of Traditional Chinese Medicine(SF-HSTCM). Additional indicators include the Acceptability Questionnaire and Health Economics Evaluation (cost-effectiveness analysis) to assess acceptability and economic practicality of the treatment in study. Outcomes are assessed at baseline and post intervention. Discussion: Electro-acupuncture and MRI-navigated rTMS therapy could become an alternative treatment for PSD, and it is expected that this trial will provide reliable clinical evidence and potential effect mechanism for the future use of electro-acupuncture and MRI-navigated rTMS for PSD.


Recruitment information / eligibility

Status Recruiting
Enrollment 64
Est. completion date August 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: Inclusion criteria for patients: - Meet the TCM and Western medicine diagnostic criteria for first onset stroke within 6 months; - Aged 40-75 years; - Right-handed; - Single infarct in basal ganglia (volume:3-5cm); - Motor evoked potential (MEP) could be recorded by bilateral primary motor cortex (M1) stimulating. - National Institutes of Health Stroke Scale (NIHSS) score <6; - Hamilton Depression Scale-24 items (HAMD-24) score > 8; - Clear consciousness, no hearing and visual impairment, and cooperative physical examination (Glasgow Coma Scale (GCS) score > 8); - Complete the screening, and sign the informed consent form voluntarily. Inclusion criteria for healthy subjects: - Healthy subjects, aged 40-75 years; - Right-handed; - HAMD-24 score < 8; - Sign the informed consent voluntarily. Exclusion Criteria: Exclusion criteria for patients: - Have received other antidepressant therapy or involved in other clinical trials in 2 weeks; - Infarct was located in the left DLPFC; - With positive psychiatric history and major trauma exposure history, such as depression, epilepsy, etc. in the past; - With other serious concomitant diseases (aphasia, severe edema, venous thrombosis, arteriosclerosis occlusion, diabetic vascular disease, peripheral neuropathy, spinal lesions, brain trauma, intracranial infection, brain tumors, etc.), and secondary diseases (heart, liver, renal failure, etc.); - Infection around acupoints and/or intolerance of acupuncture manipulation; - With MRI or rTMS contraindications (claustrophobia, metal implants, cochlear implants, impulsator, etc.). Exclusion criteria for healthy subjects: - Have involved in other clinical trials in 2 weeks; - With positive psychiatric history and major trauma exposure history, including depression, epilepsy, etc. in the past; - With MRI or rTMS contraindications (claustrophobia, metal implants, cochlear implants, impulsator, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
electro-acupuncture
Acupoints consist of Neiguan (PC6, bilateral), Shuigou (GV26), Sanyinjiao (SP6, affected side), Yintang (EX-HN3), Shangxing (GV23), Baihui (GV20), and Sishencong (EX-HN1). Disposable stainless-steel needles (0.25mm× 40 mm)will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensation of achiness, heaviness, and numbness (known as de qi) at all acupoints. Following needle manipulations, electroacupuncture instruments(SDZ-V) will be used to attached the needle handles at EX-HN3, GV23, GV20 and EX-HN1 with a dilatational wave of 5 ~ 10 Hz and a current intensity of 1 ~ 3 mA depending on the patient's tolerance. The needles will be removed after 30 minutes except for GV26 without needle retention. Participants will receive 12-20 electroacupuncture sessions over four weeks at a frequency of 3-5 times per week.
MRI-navigated rTMS
MRI:All MRI scans were taken to acquire high-resolution T1-weighted anatomical images on the 3T MRI Scanner. Electromyography(EMG):Surface EMG was used to record MEPs from the abductor pollicis brevis for determining RMT of the non-lesioned motor cortex.A single TMS pulse was delivered to the location to identify the RMT,defined as the minimum intensity capable of evoking at least 5 MEPs of >50 µV in 10 consecutive trials.MRI-navigated rTMS:Using BrainSight system,left DLPFC targeting was individualized by reconstructing MRI data into a 3-dimensional brain image for neuro-navigation. Left DLPFC localization was central middle frontal gyrus,between superior frontal sulcus and middle frontal sulcus based on T1-weighted anatomical images.Focal rTMS was administered using a Magstim Rapid 2 connected to Y125-round coil that was identical.rTMS was applied at 110% RMT to the left DLPFC.At each session,3000 pulses were applied at 10 Hz with a total of 12-20 rTMS sessions over a 4-week period.

Locations

Country Name City State
China Drum Tower Hospital, Medical School of Nanjing University Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Acceptability Questionnaire It is involved three levels: "fully accepted", "acceptable" and "not acceptable". The acceptance rate is calculated by the number of "fully accepted" and "acceptable" subjects. And higher rate mean a better outcome. 4 weeks
Other Health Economics Evaluation Cost-effectiveness analysis 4 weeks
Primary Hamilton Depression Scale-24 items scores Reduction rate change from baseline to week 4
Primary fMRI scan Cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity 0 week
Primary fMRI scan Cortical morphology, local spontaneous brain activity, and default mode network (DMN) functional connectivity 4 weeks
Secondary motor evoked potential test Cortical excitability 0 week
Secondary motor evoked potential test Cortical excitability 4 weeks
Secondary National Institutes of Health Stroke Scale The minimum and maximum values are 0 and 42 points, and higher scores mean a worse outcome. 0 week
Secondary National Institutes of Health Stroke Scale The minimum and maximum values are 0 and 42 points, and higher scores mean a worse outcome. 4 weeks
Secondary EuroQol Five Dimensions Questionnaire Scale The minimum and maximum values of utility index are -0.391 and 1 points, and higher scores mean a better outcome. 0 week
Secondary EuroQol Five Dimensions Questionnaire Scale The minimum and maximum values of utility index are -0.391 and 1 points, and higher scores mean a better outcome. 4 weeks
Secondary Modified Barthel Index Scale The minimum and maximum values are 0 and 100 points, and higher scores mean a better outcome. 0 week
Secondary Modified Barthel Index Scale The minimum and maximum values are 0 and 100 points, and higher scores mean a better outcome. 4 weeks
Secondary Short Form-Health Scale of Traditional Chinese Medicine The minimum and maximum values are 0 and 130 points, and higher scores mean a worse outcome. 0 week
Secondary Short Form-Health Scale of Traditional Chinese Medicine The minimum and maximum values are 0 and 130 points, and higher scores mean a worse outcome. 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1